TScan Therapeutics, Inc. 8-K

What Happened

• On May 6, 2026, TScan Therapeutics, Inc. (TCRX) filed a Form 8-K to announce its financial results for the quarter ended March 31, 2026. The company furnished a press release reporting its quarterly results as Exhibit 99.1 to the Form 8-K.
• The filing specifically states that the information in the Form 8-K and the press release is being “furnished” (not “filed”) under the Securities Exchange Act and is not incorporated by reference into other filings unless expressly stated.

Key Details

• Filing date: May 6, 2026 (Form 8-K, Item 2.02).
• Reporting period: Quarter ended March 31, 2026 (Q1 2026 quarterly results).
• Press release containing the detailed earnings/financial results is furnished as Exhibit 99.1 to the Form 8-K.
• Company note: Information furnished is not subject to Section 18 liability and is not automatically incorporated by reference into future SEC filings.

Why It Matters

• The press release contains TScan’s latest quarterly results—earnings, revenue, and other financial metrics—that investors use to assess the company’s financial health, cash runway, and operational progress.
• Because the detailed figures are provided in the furnished Exhibit 99.1, investors should review that press release for specifics (revenue, net loss, cash position, guidance) before drawing conclusions or making investment decisions.